ALACHUA, Fla.--(BUSINESS WIRE)--CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the Company’s Scientific Advisory Board endorsed Alzheimer’s Disease as the company’s next drug development indication. The Scientific Advisory Board met via videoconference on July 17, 2019. The endorsement was made based on the company’s data from an ongoing expanded access program in late-onset Alzheimer’s Disease with Trappsol® Cyclo™ and on data from two ongoing trials using Trappsol® Cyclo™ in Niemann-Pick Disease Type C, a rare genetic disease which may also lead to cognitive decline. The expanded access program in late-onset Alzheimer’s Disease is now in its second year. CTD’s Niemann-Pick Disease Type C trials and the expanded access program in Alzheimer’s are based on intravenous administration of the drug.
CTD Chairman and CEO N. Scott Fine said, “CTD is grateful to the Scientific Advisory Board for its insights and its work. We will move forward to build and launch a clinical trial in Alzheimer’s Disease.”
The Scientific Advisory Board is led by two Co-Chairs: Rita Colwell, PhD, Distinguished University Professor both at the University of Maryland at College Park and at Johns Hopkins University Bloomberg School of Public Health, and former Director of the National Science Foundation, and Sharon Hrynkow, PhD, CTD’s Chief Scientific Officer and Senior Vice President for Medical Affairs.
Scientific Advisory Board members are:
M. Flint Beal, MD, University Professor of Neurology and Neuroscience in the Department of Neurology and Neuroscience at the Weill Medical College of Cornell University - New York Presbyterian Hospital;
Caroline Hastings, MD, Pediatric Hematologist/Oncologist and senior clinician-scientist and educator at the UCSF Benioff Children’s Hospital, Oakland CA; and
Benny Liu, MD, Associate Division Chief of Gastroenterology at Highland Hospital in Oakland, CA and an Assistant Clinical Professor at the University of California, San Francisco (UCSF).
The Scientific Advisory Board plans to meet in late 2019 to consider additional future drug development indications.
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.ctd-holdings.com
Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.